Pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF), is administered to cancer patients to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy [1, 2]. This evidence concerns the gene CSF3 and infection.